Skip to main content
31°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syndax Pharma
(NQ:
SNDX
)
18.98
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Syndax Pharma
< Previous
1
2
3
Next >
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
October 24, 2024
Via
Benzinga
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
August 15, 2024
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious...
Via
Benzinga
Exposures
Product Safety
3 Biotech Stocks That Could Make Your Summer Unforgettable
July 30, 2024
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.
Via
InvestorPlace
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
May 29, 2024
Via
Benzinga
Syndax Pharmaceuticals: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Earnings Preview: Syndax Pharmaceuticals
February 26, 2024
Via
Benzinga
Earnings Outlook For Syndax Pharmaceuticals
November 01, 2023
Via
Benzinga
Analyst Ratings for Syndax Pharmaceuticals
October 17, 2023
Via
Benzinga
SNDX Stock Earnings: Syndax Pharmaceuticals Beats EPS for Q1 2024
May 08, 2024
SNDX stock results show that Syndax Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
February 21, 2024
Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move.
Via
Talk Markets
What's Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today?
December 11, 2023
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) shares are trading higher after the company shared data from multiple trials of revumenib in combination with standard-of-care agents in patients with...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
November 09, 2023
Via
Benzinga
What's Going On With Syndax Pharmaceuticals Stock Monday?
October 02, 2023
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) announced topline data from the AUGMENT-101 trial of revumenib in adult and pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute...
Via
Benzinga
Earnings Scheduled For August 3, 2023
August 03, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Via
Benzinga
Citigroup Maintains Buy Rating for Syndax Pharmaceuticals: Here's What You Need To Know
July 26, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Syndax Pharmaceuticals
July 25, 2023
Via
Benzinga
Earnings Scheduled For November 2, 2023
November 02, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
October 11, 2023
Via
Benzinga
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
October 02, 2023
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
October 05, 2023
On Thursday, 369 companies hit new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
September 29, 2023
Via
Benzinga
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 29, 2023
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
September 29, 2023
Friday's session saw 112 companies set new 52-week lows.
Via
Benzinga
Vail Resorts, Carnival, Opera And Other Big Stocks Moving Lower On Friday
September 29, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session. Corcept Therapeutics Incorporated (NASDAQ: CORT) shares...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Stocks That Hit 52-Week Lows On Thursday
September 21, 2023
During the session on Thursday, 461 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
September 15, 2023
Friday's session saw 169 companies set new 52-week lows.
Via
Benzinga
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
July 24, 2023
Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
September 11, 2023
Monday's session saw 175 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
July 27, 2023
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.